Alembic Pharmaceuticals Share Price Today

Alembic Pharmaceuticals to host investor meetings in Mumbai on Sep 23

Alembic Pharmaceuticals to host investor meetings in Mumbai. Sessions scheduled for September 23, 2026, starting at 10:00 am. Discussions will rely exclusively on publicly available information. Company Secretary Chirag K. Shukla issued the intimation.

USFDA issues EIR for Alembic Pharma's Vadodara bioequivalence facility

USFDA has issued an Establishment Inspection Report (EIR) for Alembic Pharmaceuticals' Vadodara bioequivalence facility. The EIR formally closes the USFDA's inspection at the said facility. The development pertains to the company's bioequivalence facility located in Vadodara.

Alembic Pharmaceuticals to host investor meetings on September 1-2

Alembic Pharmaceuticals hosts investor meetings on September 1-2, 2026. Sessions include in-person meetings in Mumbai and virtual calls. No unpublished price-sensitive information will be disclosed.

Alembic Pharmaceuticals appoints Chirag Shukla as company secretary

Chirag Shukla appointed as Company Secretary and Compliance Officer. Effective date is August 20, 2026 with permanent employment terms. Shukla brings over 19 years of experience in corporate governance. Previously worked at Deepak Phenolics and Schaeffler India Limited.

Alembic Pharmaceuticals upgrades FY27 revenue growth outlook to mid-teens

Alembic Pharmaceuticals reported a 26% revenue surge in Q1FY27 and subsequently raised its full-year growth outlook to the mid-teens. The update clarifies that the US generics segment is driving this optimism, with growth expected in the mid-to-high teens. Management also addressed margin concerns, noting a 150 bps dilution from the new US branded business in FY27, but projecting positive profit contributions from this segment starting FY28.

Alembic Pharmaceuticals declares AGM voting results; independent director appointment sees dissent

Alembic Pharmaceuticals Limited has released the voting results of its 16th AGM. Ordinary resolutions including financial statement adoption and dividend declaration received unanimous approval. The special resolution for appointing Sujit Jaysukh Bhayani as Independent Director passed with 93.08% support, though it faced significant dissent from public institutional investors.